Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

2
Player Avatar zzlangerhans (99.73) Submitted: 12/6/2011 11:16:06 PM : Underperform Start Price: $7.00 PGNX Score: +30.62

Progenics has jumped nearly 50% in two weeks from their baseline of 5 without a precipitating catalyst, and I smell stirrapulation. The 60M upfront payment from Salix for Relistor was a gift, but that's old news now and the company will surely eat up that cash. Relistor won't be bringing in much revenue even with expanded approval in April 2012, and the PSMA vaccine has been pickling in phase I for at least four years already. At least the company had the good taste to drop their sham virology program.

Featured Broker Partners


Advertisement